Why a PCAC "Yes" Vote Is Not FDA Approval

The false-signal problem

When an advisory committee votes “yes” on recommending a bulk substance for the 503A list, public coverage can sound like clearance. Committee members who vote “no” have raised exactly that concern in contemporaneous reporting: even though a PCAC vote is not drug approval, the public may treat it as an implicit safety or effectiveness endorsement.

That risk of **false signal** is distinct from a pure scientific objection. It is a communication and compliance risk for anyone summarizing the news.

What a “yes” vote actually means

A favorable PCAC vote means a majority of voting members recommended that FDA consider adding the substance (as framed on the agenda) to the 503A Bulks List. It does **not** mean:

- FDA has approved a finished drug product

- FDA has completed Category 1 listing

- The substance has been evaluated with the same standards used for NDA/BLA approval

- Compounding or commercial sale is newly authorized that day

FDA staff briefing documents may still conclude that the four-factor balance weighs against listing. The committee can disagree with staff; disagreement is advice, not override of the statute’s rulemaking requirements.

Language that stays accurate

Safer educational framing:

- “The committee recommended…”

- “The vote is non-binding…”

- “FDA must still complete rulemaking…”

- “This is not drug approval…”

Riskier framing to avoid:

- “FDA approved…”

- “Now legal to compound…”

- “Cleared for use…”

- Implying clinical outcomes or disease treatment

Bottom line

Process literacy protects readers. A PCAC “yes” is a data point in a longer administrative record — valuable to track, easy to overread.

*For research use only. Not for human or animal consumption.*